Spero reports Q2 results and tebipenem Phase 3 success; plans FDA filing in 2H 2025

Spero Therapeutics, Inc.

2025-Q2 EPS reported -$0.28 vs consensus -$0.39 ▲ beat (+27.8%)

Q2 2025 net loss $1.7M ($0.03/share) vs $17.9M ($0.33) in Q2 2024; revenue $14.2M up from $10.2M.
Phase 3 PIVOT-PO trial of tebipenem HBr in cUTI met primary endpoint; IDMC stopped early for efficacy.
Spero and GSK plan to submit data to FDA in 2H 2025; potential milestone payments adjusted to up to $101M from $150M.
Cash $31.2M at June 30 plus $23.8M GSK milestone received Aug 2025; runway expected into 2028.
Esther Rajavelu appointed CEO/President effective May 2, 2025, continuing as CFO.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.